Improving Cancer Clinical Trial Participation ... - CLL Support

CLL Support

23,088 members39,649 posts

Improving Cancer Clinical Trial Participation and Eligibility Criteria - Julia Beaver, MD, US Food and Drug Administration (FDA)

AussieNeil profile image
AussieNeilPartnerAdministrator
1 Reply

Cancer Network: How big of a problem is accrual of participants in clinical cancer treatment trials?

Dr. Beaver: Cancer trials are known to have very low accrual rates; it has been estimated that fewer than 3% of patients with cancer participate in a clinical trial. Reasons for low clinical trial accrual rates stem from patient-level, physician-level, institutional-level, and protocol-level barriers.

Full interview: cancernetwork.com/asco-stre...

Neil

Written by
AussieNeil profile image
AussieNeil
Partner
To view profiles and participate in discussions please or .
Read more about...
1 Reply
cllady01 profile image
cllady01Former Volunteer

Interesting, but concerning. The interview brought up for me the reality of aging and comorbidities---coupled with the trials excluding the very age group most likely to have comorbidities, AND, the fact that some of the drugs developed trigger the very problems that aging brings on. A conundrum to be sure.

Not what you're looking for?

You may also like...

Why 1 in 5 cancer clinical trials fizzle

"Clinical trials are the scientific soul of cancer-cure advances, but nearly 20 percent of...

Clinical trial shows sunscreen is effective in preventing UV from causing genetic damage and protects against the three forms of skin cancer

Down under, we are heading into another summer and so will need to be vigilant about sun safety,...

Mode of Progression After Frontline Treatment Predicts Clinical Outcomes in Patients With CLL

Not only is CLL heterogeneous in watch and wait, that's also the case after treatment. An analysis...

A new kid on the block? Nemtabrutinib

Hi All, There is a new targeted drug in Clinical Trials that may offer a new treatment option for...

Treatment-naive or relapsed CLL patients will soon have zanubrutinib/Brukinsa as a treatment option in the EU

The EC approval is based on positive results from two Phase 3 clinical trials: SEQUOIA...